Yes, lidocaine is an antiarrhythmic drug. It belongs to Class Ib in the Vaughan-Williams classification system, the standard framework cardiologists use to categorize heart rhythm medications. Its primary role is treating dangerous ventricular arrhythmias, particularly ventricular tachycardia and ventricular fibrillation, two conditions where the heart’s lower chambers beat too fast or chaotically to pump blood effectively.
How Lidocaine Works on the Heart
Lidocaine targets sodium channels in heart muscle cells. These channels control the electrical signals that tell the heart when to contract. Specifically, lidocaine binds to sodium channels that are in an “inactivated” state, essentially locking them in their off position for slightly longer than normal. This stabilizes the electrical activity in overexcited heart tissue without significantly affecting healthy areas that are beating normally.
This selectivity is what makes lidocaine useful. Abnormal heart tissue fires more rapidly and spends more time in that inactivated state, so lidocaine preferentially suppresses the erratic signals causing the arrhythmia while leaving normal heart rhythm mostly undisturbed. At therapeutic concentrations, this inactivated-state binding is the dominant mechanism. Research published in Circulation Research confirmed that when the inactivation process is eliminated experimentally, lidocaine loses its ability to block sodium channels entirely, even at four times the maximum therapeutic dose.
Which Arrhythmias It Treats
Lidocaine is used specifically for ventricular arrhythmias. These include ventricular premature beats (extra heartbeats originating in the lower chambers), ventricular tachycardia (a dangerously fast heart rhythm), and ventricular fibrillation (a chaotic, life-threatening rhythm where the heart quivers instead of pumping). It is not used for arrhythmias originating in the upper chambers of the heart, such as atrial fibrillation or atrial flutter.
In emergency settings, lidocaine is given intravenously. The American Heart Association’s 2025 ACLS guidelines recommend it as a first-line option alongside amiodarone for pulseless ventricular tachycardia or ventricular fibrillation that persists after three defibrillation attempts. For maintenance, it can be infused continuously at a rate of 1 to 4 milligrams per minute.
Lidocaine vs. Amiodarone in Cardiac Arrest
The two main antiarrhythmic options during cardiac arrest are lidocaine and amiodarone, and the evidence suggests they perform similarly. The largest head-to-head trial, known as ROC-ALPS, enrolled over 3,000 patients with out-of-hospital cardiac arrest. Survival to hospital discharge was 24.4% with amiodarone, 23.7% with lidocaine, and 21.0% with placebo. The difference between the two drugs was not statistically significant.
Both drugs did improve survival to hospital admission compared to placebo, and secondary analyses found that the benefit was strongest when a bystander witnessed the arrest. A 2018 meta-analysis pooling multiple studies also found no meaningful difference in survival to discharge between the two drugs. Current guidelines treat them as interchangeable first-line options, and the choice often comes down to availability and clinical preference.
Why It’s Given Intravenously
Lidocaine is almost exclusively broken down by the liver, with over 95% metabolized before it can circulate. When taken by mouth, the liver clears so much of the drug on its first pass that only about 30% reaches the bloodstream. This makes oral dosing impractical for cardiac emergencies, which is why it’s delivered directly into a vein.
In a person with normal liver function, lidocaine’s half-life is 1 to 2 hours, meaning it clears the body relatively quickly. This is actually an advantage in emergency care because if side effects develop, they resolve faster than with longer-acting drugs like amiodarone. However, in patients with heart failure or liver disease, the body’s ability to clear lidocaine drops by about 40%, which increases the risk of the drug accumulating to toxic levels.
Signs of Lidocaine Toxicity
Because lidocaine affects sodium channels throughout the body, not just in the heart, too much of it causes problems in two main systems: the brain and the cardiovascular system.
Neurological symptoms typically appear first. These include a metallic taste, numbness around the mouth, ringing in the ears, confusion, slurred speech, and in more serious cases, seizures. Seizures are the most common sign of lidocaine toxicity.
If levels continue rising, cardiovascular symptoms follow. These can include a dangerously slow heart rate, low blood pressure, new arrhythmias, and in the worst cases, cardiac arrest. The progression from early warning signs (mouth tingling, metallic taste) to severe toxicity (seizures, cardiac collapse) is the reason patients receiving IV lidocaine are closely monitored with continuous heart rhythm tracking.
Lidocaine as a Local Anesthetic
Most people encounter lidocaine not as a heart medication but as a numbing agent at the dentist’s office or during minor medical procedures. The same sodium channel-blocking mechanism that suppresses abnormal heart rhythms also blocks pain signals in nerves. The difference is entirely about how and where it’s delivered. A small injection near a nerve numbs a specific area. An intravenous infusion at controlled doses targets the heart. The underlying pharmacology is the same, just applied to different tissues at different concentrations.